Miniature organs grown in the lab can organize themselves into complex shapes. But they never do it the same way twice, which makes it hard to use these so-called “organoids” to study disease. Now, scientists at UC San Francisco have created a new material that helps organoids grow in a more predictable way.
Now, a team of researchers from Brown University, Rhode Island Hospital, and VA Providence Healthcare has shown progress in restoring two-way communication across a damaged site of the spinal cord.
An enigmatic type of circulating tumor cell called a dual-positive (DP) cell is associated with shorter survival time in patients with advanced breast cancer, according to a study led by investigators at Weill Cornell Medicine and NewYork-Presbyterian.
ANDOVER, Mass. and HAIFA, Israel, March 11, 2026 /PRNewswire/ — MeMed, a leader in advanced host-response diagnostics, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) to MeMed BV Flex™, a test designed to accurately distinguish between bacterial and viral infections based on the body’s immune response.
WESTBOROUGH, Mass., March 11, 2026 /PRNewswire/ — Olympus Corporation proudly announces the U.S. launch of the VISERA ELITE™ III surgical imaging platform designed to enhance surgical visualization, workflow efficiency, and multispecialty flexibility. The VISERA ELITE III platform is a significant leap forward in surgical imaging and the third major co-developed product by SONY Olympus Medical (SOMED), a joint venture established in 2013.
View offers 2D and 3D visualisation, along with AI-based tools, to assist in clinical decision making.
OncoPatch announced today that it received FDA 510(k) for its Oncopatch Surface brachytherapy system for treating localized tumors.
MiniMed (Nasdaq:MMED) announced that it received CE mark for the use of its MiniMed 780G with the Instinct sensor made by Abbott.
Matthew Jones is using experimental technology and computation to decode the molecular processes that underlie the way tumors evolve to resist treatment by pinpointing how and when aggressive mutations arise.
Leveraging the potential of NfL as a biomarker, researchers from Japan have developed the world’s first aptamer (tiny, single-stranded synthetic DNA molecules) that can bind NfL with high affinity and specificity